Somewhat Positive Press Coverage Somewhat Unlikely to Affect TrovaGene (TROV) Share Price

News headlines about TrovaGene (NASDAQ:TROV) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TrovaGene earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 48 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

Separately, Maxim Group reissued a “buy” rating and set a $4.00 target price on shares of TrovaGene in a research note on Tuesday, June 13th.

TrovaGene (NASDAQ:TROV) traded down 2.94% during mid-day trading on Thursday, hitting $0.99. 496,387 shares of the company traded hands. The stock’s market capitalization is $30.66 million. The company’s 50-day moving average is $1.05 and its 200-day moving average is $1.37. TrovaGene has a one year low of $0.61 and a one year high of $5.98.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://baseballnewssource.com/markets/trovagene-trov-receives-daily-coverage-optimism-rating-of-0-19-updated/1169404.html.

About TrovaGene

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Insider Buying and Selling by Quarter for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base


Leave a Reply

 
© 2006-2017 BBNS.